Skip to content

Study · Randomized controlled trial · n = 17 · 1995

4 results

A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency.

Guevara-Aguirre J, Vasconez O, Martinez V, Martinez AL, Rosenbloom AL, Diamond FB Jr, Gargosky SE, Nonoshita L, Rosenfeld RG

The Journal of clinical endocrinology and metabolism1 Apr 1995Cited by 70 (Europe PMC)

PMID7536209 (opens in a new tab)DOI10.1210/jcem.80.4.7536209 (opens in a new tab)PepBankPUB-07536209
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In children with GH receptor deficiency, hypoglycemia frequency was equal with rhIGF-I and placebo.

    In plain wordsIn children with GH receptor deficiency, low blood sugar occurred equally often with rhIGF-I and placebo.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeHypoglycemia frequency
    Study

    n = 17

    Comparator
    Placebo
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    120 micrograms/kg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Incidents of hypoglycemia were equal in frequency in the placebo and rhIGF-I groups.
    2 context sentences
    Summary · context
    Seventeen prepubertal patients were entered in a randomized, double blind, placebo-controlled trial.
    Summary · context
    Subjects received either a 12-month course of rhIGF-I (120 micrograms/kg, sc, daily) or 6 months of placebo followed by 6 months of rhIGF-I.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In children with GH receptor deficiency, rhIGF-I increased growth rate from 2.9 to 8.6 cm/yr, sustained over therapy.

    In plain wordsIn children with GH receptor deficiency, rhIGF-I increased growth rate, sustained over therapy.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseGrowth rate
    Study

    n: not reported in source

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    120 micrograms/kg daily · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Growth rate
    2.9 cm/yr
    rhIGF-I recipients, before therapy (2.9 +/- 0.6)
    Growth rate
    8.6 cm/yr
    rhIGF-I recipients, on therapy (8.6 +/- 0.4)
    Growth rate +/- uncertainty magnitude (type not stated)
    0.6 cm/yr
    rhIGF-I recipients, before therapy, 2.9 +/- 0.6
    Growth rate +/- uncertainty magnitude (type not stated)
    0.4 cm/yr
    rhIGF-I recipients, on therapy, 8.6 +/- 0.4

    Source sentences

    Summary
    Subjects receiving rhIGF-I showed a significant increase in growth rate, which was sustained over the 1-yr course of therapy (from 2.9 +/- 0.6 to 8.6 +/- 0.4 cm/yr).
    2 context sentences
    Summary · context
    Seventeen prepubertal patients were entered in a randomized, double blind, placebo-controlled trial.
    Summary · context
    Subjects received either a 12-month course of rhIGF-I (120 micrograms/kg, sc, daily) or 6 months of placebo followed by 6 months of rhIGF-I.
  3. 03HumanRandomized controlled trialSafety outcome

    One child receiving rhIGF-I developed papilledema, which resolved spontaneously.

    In plain wordsOne child receiving rhIGF-I developed swelling of the optic disc, which resolved spontaneously.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    Not applicablePapilledema
    Study

    n: not reported in source

    Outcome group
    Adverse events · Eye
    Studied dose
    120 micrograms/kg daily · subcutaneousAs given in this study (human).

    Measurements

    Participants with papilledema
    1 participants
    rhIGF-I recipients

    Source sentences

    Summary
    One recipient of rhIGF-I developed papilledema, which resolved spontaneously.
    2 context sentences
    Summary · context
    Seventeen prepubertal patients were entered in a randomized, double blind, placebo-controlled trial.
    Summary · context
    Subjects received either a 12-month course of rhIGF-I (120 micrograms/kg, sc, daily) or 6 months of placebo followed by 6 months of rhIGF-I.
  4. 04HumanRandomized controlled trialMechanism

    In children with GH receptor deficiency, rhIGF-I did not alter serum IGF-binding protein-3 concentrations.

    In plain wordsIn children with GH receptor deficiency, rhIGF-I did not alter serum IGF-binding protein-3 concentrations.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeIGF-binding protein-3
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    120 micrograms/kg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    rhIGF-I therapy did not alter serum IGF-binding protein-3 concentrations.
    2 context sentences
    Summary · context
    Seventeen prepubertal patients were entered in a randomized, double blind, placebo-controlled trial.
    Summary · context
    Subjects received either a 12-month course of rhIGF-I (120 micrograms/kg, sc, daily) or 6 months of placebo followed by 6 months of rhIGF-I.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.